Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson?s disease and other neurodegenerative diseases
The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Iron has been shown to accumulates at site where neurons degenerate in neurodegenerative diseases of Parkinson's disease, Alzheimer's disease, Huntington disease, amyotrophic lateral sclerosis and Friedreich ataxia. Iron is thought to participate or initiate oxidative stress via generation of reactive oxygen species (ROS), such as hydroxyl radical. Iron chelators are neuroprotective and prevent 6-hydroxydoapmine and MPTP dopaminergic neurotoxicity in rats and mice. However, their action on monoamine oxidase (MAO) A and B have not been determined previously since MAO-B inhibitors have been shown to be neuroprotective in cellular and animal models of Parkinson's disease. The chelators 8-hydroxyquinoline, O-phenanthroline, 2,2'-dipyridyl, U74500A and U74600F showed a preference for inhibition of rat brain mitochondrial MAO-A over MAO-B. Their IC(50) ranged from 10(-3) M to 10(-6) M, with 21-amino steroids (U74500A and U74006F) showing a greater selectivity and potency for MAO-A. Desferrioxamine (desferal), a prototype potent iron chelator, exhibited relatively poor MAO inhibitory. The inhibitions of MAO-A and B by 21-amino steroids (Lazaroids) were time dependent and irreversible. Those initiated by 8-hydroxyquinoline, 2,2'-dipyridyl and O-phenanthroline were fully reversible by enzyme dilution experiments. Both Fe(2+) and Fe(3+) reverse the MAO-A and B inhibition induced by the latter chelators, but not those initiated by 21-amino steroids. The data infer that either the inhibition of MAO by 21-amino steroids is either the resultant of their conversion to an irreversible covalently bound ligand or that the iron chelation moiety and MAO inhibitory activity in these compounds are not mutually shared. The results suggest that bifunctional brain penetrable drugs with iron chelating property and MAO inhibitory activity in could be the most feasible approach for neuroprotection in neurodegenerative diseases. Such drug would prevent participation of elevated iron in oxidative stress and formation of reactive hydroxyl radical, via its interaction with H(2)O2 (Fenton chemistry), generated as a consequence MAO and other oxidative enzyme reactions to generative cytotoxic reactive hydroxyl radical. We have now developed several of these compounds with neuroprotective, MAO inhibitory and iron chelating properties from our prototype iron chelators, VK-28 possessing propargylamine moiety of our anti-parkinson drug, rasagiline.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, iron chelators have demonstrated therapeutic benefits in Alzheimer's [1674,1710,1769-1771], Parkinson's [1037,1729,1772], cold-induced brain injury [1773,1774], coronary disease [714,797], renal diseases [1775], various kinds of infection [1763] and of course in iron overload diseases [1762,1767].”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1037]
In the citing paper
“To this end, Youdim and colleagues in particular have developed a series of multifunctional 8-hydroxyquinoline [1740] derivatives that are effective bidentate iron chelators and that seem to show considerable promise in the treatment of a variety of neurodegenerative diseases [1037,1727-1729,1780-1784]”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1037]
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 2×
“Protein was estimated according to Bradford (1976) using human serum albumin as standard.”
MethodHalliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy‐Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397 · cited 2×
“…brains there are increases of MAOB activity (Birkmayer et al., 1975; Oreland and Gottfries, 1986) and iron (Sofic et al., 1988; Riederer et al., 1989; Dexter et al., 1989; Youdim et al., 1993; Jellinger, 1999; Smith and Perry, 1995; Cuajungco et al., 2000; Bush, 2002; Gerlach et al., 2003; Youdim,…”
BackgroundTransition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383 · cited 9×
“…Alzheimer’s diseases brains there are increases of MAOB activity (Birkmayer et al., 1975; Oreland and Gottfries, 1986) and iron (Sofic et al., 1988; Riederer et al., 1989; Dexter et al., 1989; Youdim et al., 1993; Jellinger, 1999; Smith and Perry, 1995; Cuajungco et al., 2000; Bush, 2002;…”
BackgroundSelf-citationEffects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149 · cited 3×
“…brains there are increases of MAOB activity (Birkmayer et al., 1975; Oreland and Gottfries, 1986) and iron (Sofic et al., 1988; Riederer et al., 1989; Dexter et al., 1989; Youdim et al., 1993; Jellinger, 1999; Smith and Perry, 1995; Cuajungco et al., 2000; Bush, 2002; Gerlach et al., 2003; Youdim,…”
BackgroundOxidative stress and the pathogenesis of Parkinson's disease
Jenner, P., & Olanow, C. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.161s · Cited by 971 · cited 1×
“…that the etiology of Parkinson’s and Alzheimer’s diseases may be closely linked to biochemical changes resultant from oxidative stress (Cohen, 2002; Riederer et al., 1989; Jenner and Olanow, 1996; Gerlach et al., 1994; Smith and Perry, 1995; Youdim et al., 1999; Youdim, 2003; Gerlach et al., 2003).”
BackgroundEffect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G., & Youdim, M. B. H. (1988) · Journal of Neural Transmission · doi:10.1007/bf01244786 · Cited by 752 · cited 3×
“…been proposed for Parkinson’s disease and Alzheimer’s disease, where highly significant accumulation of iron occurs in substantia nigra pars compacta (Sofic et al., 1988; Riederer et al., 1989; Jellinger et al., 1990; Jellinger, 1999) and within the pigmented-melanized dopamine neurons (Jellinger…”
BackgroundSelf-citationAltered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases?
Gerlach, M., Ben‐Shachar, D., Riederer, P., & Youdim, M. B. H. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63030793.x · Cited by 703 · cited 2×
“…that the etiology of Parkinson’s and Alzheimer’s diseases may be closely linked to biochemical changes resultant from oxidative stress (Cohen, 2002; Riederer et al., 1989; Jenner and Olanow, 1996; Gerlach et al., 1994; Smith and Perry, 1995; Youdim et al., 1999; Youdim, 2003; Gerlach et al., 2003).”
BackgroundSelf-citationGenetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620 · cited 2×
“Its confirmation has come from genetic and pharmacological studies in prevention of MPTP by a copper chelator neurotoxicity (Kaur et al., 2003).”
BackgroundA Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
(2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1937 · Cited by 579
Levites, Y., Weinreb, O., Maor, G., Youdim, M. B. H., & Mandel, S. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00490.x · Cited by 567 · cited 1×
“However, they are relatively poor inhibitors of brain mitochondrial MAO (Grunblatt et al., 2001; Levites et al., 2001).”
BackgroundSelf-citationBrain iron and ferritin in Parkinson’s and Alzheimer’s diseases
Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., & Youdim, M. B. H. (1990) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02252926 · Cited by 445 · cited 2×
“…disease, where highly significant accumulation of iron occurs in substantia nigra pars compacta (Sofic et al., 1988; Riederer et al., 1989; Jellinger et al., 1990; Jellinger, 1999) and within the pigmented-melanized dopamine neurons (Jellinger et al., 1992) and in the hallow Lewy body…”
BackgroundSelf-citationGlutathione, iron and Parkinson’s disease
Bharath, S., Hsu, M., Kaur, D., Rajagopalan, S., & Andersen, J. K. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01174-7 · Cited by 396
Birkmayer, W., Riederer, P., Youdim, M. B. H., & Linauer, W. (1975) · Journal of Neural Transmission · doi:10.1007/bf01253131 · Cited by 363 · cited 2×
“…Baron sitting in his hall But iron, cold iron is master of all In Parkinson’s and Alzheimer’s diseases brains there are increases of MAOB activity (Birkmayer et al., 1975; Oreland and Gottfries, 1986) and iron (Sofic et al., 1988; Riederer et al., 1989; Dexter et al., 1989; Youdim et al., 1993;…”
BackgroundSelf-citationIron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis
Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben‐Shachar, D., & Youdim, M. B. H. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08362.x · Cited by 313 · cited 1×
“…highly significant accumulation of iron occurs in substantia nigra pars compacta (Sofic et al., 1988; Riederer et al., 1989; Jellinger et al., 1990; Jellinger, 1999) and within the pigmented-melanized dopamine neurons (Jellinger et al., 1992) and in the hallow Lewy body (Jellinger et al., 1992).”
BackgroundSelf-citationMetal complexing agents as therapies for Alzheimer’s disease
Bush, A. I. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00120-3 · Cited by 310 · cited 2×
“…(Sofic et al., 1988; Riederer et al., 1989; Dexter et al., 1989; Youdim et al., 1993; Jellinger, 1999; Smith and Perry, 1995; Cuajungco et al., 2000; Bush, 2002; Gerlach et al., 2003; Youdim, 2003; Double et al., 2003) and a progressive decrease in reduced glutathione (GSH) (Riederer et al.,…”
BackgroundThe possible role of iron in the etiopathology of parkinson's disease
Youdim, M. B. H., Ben‐Shachar, D., & Riederer, P. (1993) · Movement Disorders · doi:10.1002/mds.870080102 · Cited by 301 · cited 2×
“, 1975; Oreland and Gottfries, 1986) and iron (Sofic et al., 1988; Riederer et al., 1989; Dexter et al., 1989; Youdim et al., 1993; Jellinger, 1999; Smith and Perry, 1995; Cuajungco et al., 2000; Bush, 2002; Gerlach et al., 2003; Youdim, 2003; Double et al., 2003) and a progressive decrease in reduced glutathione (GSH…”
BackgroundSelf-citationBen‐Shachar, D., Eshel, G., Finberg, J. P. M., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb11444.x · Cited by 299 · cited 2×
“…of iron overload (thalasemia major) does not penetrate the blood brain barrier, but protects against 6-hydroxydopamine and MPTP induced lesion of nigra striatal dopamine neurons in rats and mice when injected intra ventricularly (Ben-Shachar et al., 1991; Lan and Jiang, 1997; Youdim et al., 2004).”
BackgroundSelf-citationShachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., & Youdim, M. B. H. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.005 · Cited by 246 · cited 8×
“The iron chelator desferrioxamine (desferal), used clinically in the treatment of iron overload (thalasemia major) does not penetrate the blood brain barrier, but protects against 6-hydroxydopamine and MPTP induced lesion of nigra striatal dopamine neurons in rats and mice when injected intra ventricularly (Ben-Shacha…”
BackgroundSelf-citationLinert, W., Herlinger, E., Jameson, R. F., Kienzl, E., Jellinger, K., & Youdim, M. B. H. (1996) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(96)00020-8 · Cited by 238 · cited 2×
“…of reactive oxygen specie (ROS) and release of feritin bound iron and loss of reduced glutathione (GSH) (Hall et al., 1992; Borisenko et al., 2000; Youdim et al., 2004; Linert et al., 1996; Lode et al., 1997; Braughler et al., 1988) and deposition of iron (Hall et al., 1992; Temlett et al., 1994).”
BackgroundSelf-citationNeuroprotective Strategies in Parkinson???s Disease: An Update on Progress
Mandel, S., Gr??nblatt, E., Riederer, P., Gerlach, M., Levites, Y., & Youdim, M. B. H. (2003) · CNS Drugs · doi:10.2165/00023210-200317100-00004 · Cited by 237
Self-citationYOUDIM, M. B. H., STEPHENSON, G., & SHACHAR, D. B. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.025 · Cited by 233 · cited 4×
“…of iron overload (thalasemia major) does not penetrate the blood brain barrier, but protects against 6-hydroxydopamine and MPTP induced lesion of nigra striatal dopamine neurons in rats and mice when injected intra ventricularly (Ben-Shachar et al., 1991; Lan and Jiang, 1997; Youdim et al., 2004).”
BackgroundSelf-citationFaucheux, B. A., Martin, M., Beaumont, C., Hauw, J., Agid, Y., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01923.x · Cited by 229
The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease
Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218 · cited 4×
“…highly significant accumulation of iron occurs in substantia nigra pars compacta (Sofic et al., 1988; Riederer et al., 1989; Jellinger et al., 1990; Jellinger, 1999) and within the pigmented-melanized dopamine neurons (Jellinger et al., 1992) and in the hallow Lewy body (Jellinger et al., 1992).”
BackgroundInfluentialMetal Chelation as a Potential Therapy for Alzheimer's Disease
CUAJUNGCO, M. P., FAGÉT, K. Y., HUANG, X., TANZI, R. E., & BUSH, A. I. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06938.x · Cited by 215 · cited 2×
“…1986) and iron (Sofic et al., 1988; Riederer et al., 1989; Dexter et al., 1989; Youdim et al., 1993; Jellinger, 1999; Smith and Perry, 1995; Cuajungco et al., 2000; Bush, 2002; Gerlach et al., 2003; Youdim, 2003; Double et al., 2003) and a progressive decrease in reduced glutathione…”
BackgroundBinda, C., Hubálek, F., Li, M., Herzig, Y., Sterling, J., Edmondson, D. E., & Mattevi, A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031087c · Cited by 214 · cited 2×
“…are substrate for the enzyme and are metabolized by it to the active inhibitory component, which binds irreversibly with the FDA cofactor of the enzyme at the active site covalently (see Youdim et al., 1988; see for reviews, Edmondson et al., 2004; Hubalek et al., 2004; Binda et al., 2004).”
BackgroundUse of desferrioxamine in the treatment of aceruloplasminemia
Miyajima, H., Takahashi, Y., Kamata, T., Shimizu, H., Sakai, N., & Gitlin, J. D. (1997) · Annals of Neurology · doi:10.1002/ana.410410318 · Cited by 173 · cited 2×
“…neuroprotection in neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington disease, amyotrophic lateral sclerosis, aceruloplasminemia (Miyajima et al., 1997) and Friedreich ataxia where iron misregulation has consistently been described (Youdim and Riederer, 2004).”
BackgroundDesferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
Lan, J., & Jiang, D. H. (1997) · Journal of Neural Transmission · doi:10.1007/bf01277665 · Cited by 159 · cited 2×
“…of iron overload (thalasemia major) does not penetrate the blood brain barrier, but protects against 6-hydroxydopamine and MPTP induced lesion of nigra striatal dopamine neurons in rats and mice when injected intra ventricularly (Ben-Shachar et al., 1991; Lan and Jiang, 1997; Youdim et al., 2004).”
BackgroundTatton, W. G., Chalmers-Redman, R. M. E., Ju, W., Mammen, M., Carlile, G. W., Pong, A., & Tatton, N. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.753 · Cited by 147 · cited 1×
“…have been shown to possess neuroprotective activity and prevent neuronal cell death unrelated to their MAO inhibitory activity (Maruyama and Naoi, 1999; Maruyama et al., 2001; Tatton et al., 2002, 2003; Youdim, 2003) we have examined the neuroprotective activity of the bifunctional compounds (Fig.”
BackgroundApomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction
Gassen, M., Glinka, Y., Pinchasi, B., & Youdim, M. B. H. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00291-9 · Cited by 140 · cited 1×
“…a dopamine D1–D2 receptor agonist and green tea polyphenol, EGCG, are not only relatively potent radical scavengers but they are also chelators of iron (Gassen et al., 1996, see Mandel et al., 2004 for review) and protect against 6-hydroxydopamine and MPTP neurotoxicity (Mandel et al., 2004).”
BackgroundSelf-citationYOUDIM, M. B. H., WADIA, A., TATTON, W., & WEINSTOCK, M. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03656.x · Cited by 140 · cited 3×
“We have therefore synthesized several derivatives of VK-28 on which we introduced the propargylamine MAO inhibitory moiety of the neuroprotective antiParkinson MAO B inhibitor drug, rasagiline (Youdim et al., 2001a, b; Parkinson Study Group, 2002; Youdim, 2003) (Fig.”
BackgroundMethodSelf-citationTatton, W. G., Chalmers-Redman, R. M. E., & Tatton, N. A. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0827-z · Cited by 139 · cited 2×
“…have been shown to possess neuroprotective activity and prevent neuronal cell death unrelated to their MAO inhibitory activity (Maruyama and Naoi, 1999; Maruyama et al., 2001; Tatton et al., 2002, 2003; Youdim, 2003) we have examined the neuroprotective activity of the bifunctional compounds (Fig.”
BackgroundTemlett, J. A., Landsberg, J. P., Watt, F., & Orime, G. W. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62010134.x · Cited by 137 · cited 2×
“et al., 1996; Lode et al., 1997; Braughler et al., 1988) and deposition of iron (Hall et al., 1992; Temlett et al., 1994 ).”
BackgroundGassen, M., Gross, A., & Youdim, M. B. H. (1998) · Movement Disorders · doi:10.1002/mds.870130208 · Cited by 134
Self-citationFree radical damage, iron, and Alzheimer's disease
Smith, M. A., & Perry, G. L. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00213-l · Cited by 131 · cited 4×
“…that the etiology of Parkinson’s and Alzheimer’s diseases may be closely linked to biochemical changes resultant from oxidative stress (Cohen, 2002; Riederer et al., 1989; Jenner and Olanow, 1996; Gerlach et al., 1994; Smith and Perry, 1995; Youdim et al., 1999; Youdim, 2003; Gerlach et al., 2003).”
BackgroundInfluentialBrain and brain monoamine oxidase in aging and in dementia of Alzheimer's type
Oreland, L., & Gottfries, C. (1986) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(86)90023-0 · Cited by 129 · cited 2×
“B activity (Birkmayer et al., 1975; Oreland and Gottfries, 1986 ) and iron (Sofic et al., 1988; Riederer et al., 1989; Dexter et al., 1989; Youdim et al., 1993; Jellinger, 1999; Smith and Perry, 1995; Cuajungco et al., 2000; Bush, 2002; Gerlach et al., 2003; Youdim, 2003; Double et al., 2003) and a progressive decreas…”
BackgroundYogev-Falach, M., Amit, T., Bar-Am, O., & Youdim, M. B. H. (2003) · The FASEB Journal · doi:10.1096/fj.03-0078fje · Cited by 118 · cited 1×
“These include prevention of cell (PC-12, SHSY-5Y) death in absence of serum and NGF, up regulation of the gene expression and proteins of antiapoptotic Bcl-2 and Bcl-xl and activation of PKCa and e (Yogev-Falach et al., 2003; Bar Am et al., 2004a, b).”
BackgroundSelf-citationGerlach, M., Double, K. L., Ben‐Shachar, D., Zecca, L., Youdim, M. B. H., & Riederer, P. F. (2003) · Neurotoxicity Research · doi:10.1007/bf03033371 · Cited by 116
Self-citationOxidative Stress, Mitochondrial Respiration, and Parkinson's Disease
COHEN, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06180.x · Cited by 115
MARUYAMA, W., YOUDIM, M. B. H., & NAOI, M. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03641.x · Cited by 111
Self-citationYogev‐Falach, M., Amit, T., Bar‐Am, O., Weinstock, M., & Youdim, M. B. H. (2002) · The FASEB Journal · doi:10.1096/fj.02-0198fje · Cited by 104 · cited 2×
“This phenomenon has been well described for tight binding reversible MAO-B inhibitors such as MPTP ( Tipton et al., 1986 ), Lazabamide (Cesura et al., 1990) and milacemide (Janssen de Varebeke et al., 1989), moclobamide, etc., which are substrates as well as enzyme activated inhibitors of MAO-A and MAO-B.”
BackgroundSelf-citationIron involvement in neural damage and microgliosis in models of neurodegenerative diseases.
Shoham, S., & Youdim, M. B. H. (2000) · PubMed · Cited by 102
Self-citationThe FAD Binding Sites of Human Monoamine Oxidases A and B
Edmondson, D. E. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(03)00114-1 · Cited by 98 · cited 1×
“…are substrate for the enzyme and are metabolized by it to the active inhibitory component, which binds irreversibly with the FDA cofactor of the enzyme at the active site covalently (see Youdim et al., 1988; see for reviews, Edmondson et al., 2004; Hubalek et al., 2004; Binda et al., 2004).”
BackgroundEffects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
Grunblatt, E., Mandel, S., Maor, G., & Youdim, M. B. H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.t01-1-00227.x · Cited by 96 · cited 1×
“However, they are relatively poor inhibitors of brain mitochondrial MAO (Grunblatt et al., 2001; Levites et al., 2001).”
BackgroundSelf-citationHubálek, F., Binda, C., Li, M., Herzig, Y., STERLING, J. J., Youdim, M. B. H., Mattevi, A., & Edmondson, D. E. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0310885 · Cited by 94 · cited 2×
“…are substrate for the enzyme and are metabolized by it to the active inhibitory component, which binds irreversibly with the FDA cofactor of the enzyme at the active site covalently (see Youdim et al., 1988; see for reviews, Edmondson et al., 2004; Hubalek et al., 2004; Binda et al., 2004).”
BackgroundSelf-citationGluck, M. R., Krueger, M. J., Ramsay, R. R., Sablin, S. O., Singer, T. P., & Nicklas, W. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41844-8 · Cited by 92 · cited 2×
“On the other hand, other pyridinium compounds such as 2,20-dipyridyl (Youdim and Sourkes, 1965), paraquat or MPTP (N-methyl-4-phenyl-1,2,3,6tetrahydropyridine) or MPPþ (N-methyl-4-phenyl-1,2-dipyridinium) (Gluck et al., 1994; Tipton et al., 1986; Melamed and Youdim, 1985) selectively inhibit the B form of the enzyme,…”
BackgroundNovel membrane localized iron chelators as inhibitors of iron-dependent lipid peroxidation
Braughler, J. M., Burton, P. S., Chase, R. L., Pregenzer, J. F., Jacobsen, E. J., VanDoornik, F. J., Tustin, J. M., Aver, D. E., & Bundy, G. L. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90066-4 · Cited by 88 · cited 4×
“…of reactive oxygen specie (ROS) and release of feritin bound iron and loss of reduced glutathione (GSH) (Hall et al., 1992; Borisenko et al., 2000; Youdim et al., 2004; Linert et al., 1996; Lode et al., 1997; Braughler et al., 1988) and deposition of iron (Hall et al., 1992; Temlett et al., 1994).”
BackgroundInfluentialYOUDIM, M. B. H., GRÜNBLATT, E., & MANDEL, S. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07977.x · Cited by 85 · cited 2×
“…that the etiology of Parkinson’s and Alzheimer’s diseases may be closely linked to biochemical changes resultant from oxidative stress (Cohen, 2002; Riederer et al., 1989; Jenner and Olanow, 1996; Gerlach et al., 1994; Smith and Perry, 1995; Youdim et al., 1999; Youdim, 2003; Gerlach et al., 2003).”
BackgroundSelf-citationGassen, M., & Youdim, M. B. H. (1997) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1997.tb00390.x · Cited by 79
Self-citationNeuroprotection by (−)-deprenyl and related compounds
Maruyama, W., & Naoi, M. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(99)00066-4 · Cited by 71 · cited 1×
“…MAO inhibitors have been shown to possess neuroprotective activity and prevent neuronal cell death unrelated to their MAO inhibitory activity (Maruyama and Naoi, 1999; Maruyama et al., 2001; Tatton et al., 2002, 2003; Youdim, 2003) we have examined the neuroprotective activity of the…”
BackgroundInhibition of monoamine oxidase by isoquinoline derivatives
Thull, U., Kneubühler, S., Gaillard, P., Carrupt, P., Testa, B., Altomare, C., Carotti, A., Jenner, P. G., & McNaught, K. S. P. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00220-t · Cited by 63
THE EFFECT OF HEAT, INHIBITORS, AND RIBOFLAVIN DEFICIENCY ON MONOAMINE OXIDASE
Youdim, M. B. H., & Sourkes, T. L. (1965) · Canadian Journal of Biochemistry · doi:10.1139/o65-145 · Cited by 57 · cited 9×
“Previously it has been established that inhibition of MAO by 8-hydroxyquinoline is reversible in the presence of Fe2þ or Fe3þ (Youdim and Sourkes, 1965).”
BackgroundSelf-citationSang, S., Lambert, J. D., Ho, C. T., & Yang, C. S. (2004) · doi:10.1081/e-eds-120022069 · Cited by 56
MRI, brain iron and experimental Parkinson's disease
Hall, S., Rutledge, J. N., & Schallert, T. J. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90247-i · Cited by 49 · cited 7×
“…of reactive oxygen specie (ROS) and release of feritin bound iron and loss of reduced glutathione (GSH) (Hall et al., 1992; Borisenko et al., 2000; Youdim et al., 2004; Linert et al., 1996; Lode et al., 1997; Braughler et al., 1988) and deposition of iron (Hall et al., 1992; Temlett et al., 1994).”
BackgroundInfluentialRasagiline: an anti-Parkinson drug with neuroprotective activity
Youdim, M. B. (2003) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.3.6.737 · Cited by 48 · cited 12×
“…that the etiology of Parkinson’s and Alzheimer’s diseases may be closely linked to biochemical changes resultant from oxidative stress (Cohen, 2002; Riederer et al., 1989; Jenner and Olanow, 1996; Gerlach et al., 1994; Smith and Perry, 1995; Youdim et al., 1999; Youdim, 2003; Gerlach et al., 2003).”
BackgroundMethodSelf-citationInteraction between 6-Hydroxydopamine and Transferrin: “Let My Iron Go”
Borisenko, G. G., Kagan, V. E., Hsia, C. J. C., & Schor, N. F. (2000) · Biochemistry · doi:10.1021/bi992296v · Cited by 48 · cited 2×
“The dopaminergic neurotoxins 6-hydroxydopamine and MPTP owe their neurotoxicity to induction of oxidative stress resulting from production of reactive oxygen specie (ROS) and release of feritin bound iron and loss of reduced glutathione (GSH) (Hall et al., 1992; Borisenko et al., 2000; Youdim et al., 2004; Linert”
BackgroundTipton, K. F., McCrodden, J. M., & Youdim, M. B. H. (1986) · Biochemical Journal · doi:10.1042/bj2400379 · Cited by 45 · cited 4×
“This phenomenon has been well described for tight binding reversible MAO-B inhibitors such as MPTP (Tipton et al., 1986), Lazabamide (Cesura et al.”
BackgroundSelf-citationSteroid regulation of monoamine oxidase activity in the adrenal medulla
Youdim, M. B. H., Banerjee, D. K., Kelner, K. L., Offutt, L. A., & Pollard, H. B. (1989) · The FASEB Journal · doi:10.1096/fasebj.3.6.2495232 · Cited by 42 · cited 2×
“The contribution of the steroid moiety to MAO inhibition should be considered since we have shown that estrogen selectively inactivates MAO-A (Youdim et al., 1989).”
BackgroundSelf-citationNaoi, M., Maruyama, W., Akao, Y., & Yi, H. L. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200050 · Cited by 39
Youdim, M. B. H. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0643-3_5 · Cited by 38 · cited 7×
“…that the etiology of Parkinson’s and Alzheimer’s diseases may be closely linked to biochemical changes resultant from oxidative stress (Cohen, 2002; Riederer et al., 1989; Jenner and Olanow, 1996; Gerlach et al., 1994; Smith and Perry, 1995; Youdim et al., 1999; Youdim, 2003; Gerlach et al., 2003).”
BackgroundMethodSelf-citationIn vivo effect of MPTP on monoamine oxidase activity in mouse striatum
Melamed, E., Youdim, M. B. H., Rosenthal, J., Spanier, I., Uzzan, A., & Globus, M. (1985) · Brain Research · doi:10.1016/0006-8993(85)91451-9 · Cited by 37
Self-citationde Varebeke, P. J., Pauwels, G., Buyse, C., David-Remacle, M., Mey, J. G. R. D., Roba, J., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07403.x · Cited by 34 · cited 1×
“…phenomenon has been well described for tight binding reversible MAO-B inhibitors such as MPTP (Tipton et al., 1986), Lazabamide (Cesura et al., 1990) and milacemide (Janssen de Varebeke et al., 1989), moclobamide, etc., which are substrates as well as enzyme activated inhibitors of MAO-A and MAO-B.”
BackgroundSelf-citationAssay and Purification of Brain Monoamine Oxidase
Youdim, M. B. H. (1975) · Springer eBooks · doi:10.1007/978-1-4613-4458-2_5 · Cited by 22 · cited 1×
“Brain mitochondria were prepared from male Sprague-Dawely rats (200–850 g) according to the method described by Youdim (1975) as adopted from Gray and Whittaker (1964).”
MethodSelf-citationRelease of Iron from Ferritin by 6-Hydroxydopamine Under Aerobic and Anaerobic Conditions
Lode, H. N., Bruchelt, G., Rieth, A. G., & NIETHAMMER, D. (1990) · Free Radical Research Communications · doi:10.3109/10715769009109678 · Cited by 20
Ren, M.-Q., Ong, W., Wang, X., & Watt, F. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00341-8 · Cited by 15 · cited 1×
“However, in older monkeys Fe deposition in SN has been shown to exists before MPTP injection, suggesting the possibility of localized damage in neurons through the catalysis of free radicals (Ren et al., 2003).”
BackgroundCesura, A. M., Muggli-Maniglio, D., Lang, G., Imhof, R., & Prada, M. (1990) · Springer eBooks · doi:10.1007/978-3-7091-9113-2_24 · Cited by 13 · cited 3×
“This phenomenon has been well described for tight binding reversible MAO-B inhibitors such as MPTP (Tipton et al., 1986), Lazabamide (Cesura et al., 1990) and milacemide (Janssen de Varebeke et al., 1989), moclobamide, etc., which are substrates as well as enzyme activated inhibitors of MAO-A and MAO-B.”
Background
Cited by
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
“Chelators for metals such as iron that have redox potential are being developed and considered for the treatment of AD (see below”
BackgroundSelf-citationMulti-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Metals in Alzheimer's and Parkinson's Diseases
Barnham, K. J., & Bush, A. I. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.02.019 · Cited by 695
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“Iron (and in some cases copper) is also strongly implicated in a variety of neurodegenerative diseases [867] [868] [869] [870] [871] [872] [836] [873] [837] [850] [874] [875] [876] [877] [854] [878] [879] [880] [881] [842] [882] [883] [884] [885] [886] [887] [888] [889] [890] [891] [892] [893] [894] [895] [896] [897]…”
BackgroundInfluentialChong, Z. Z., Li, F., & Maiese, K. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.004 · Cited by 536
Metadata
- Authors
- Youdim, M. B. H., Fridkin, M., & Zheng, H.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- Weizmann Institute of Science (IL)
- Venue
- Journal of Neural Transmission
- Published
- 2004-04-20
- Volume
- 111
- Issue
- 10-11
- Pages
- 1455-1471
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W1967321583
- Cited by
- 123
- References
- 69
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 10 · 2012: 3
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Parkinson's disease, iron chelation, monoamine oxidase inhibition, monoamine oxidase A, monoamine oxidase B, neuroprotection, neurodegenerative diseases, oxidative stress, hydroxyl radicals, lazaroids, deferoxamine, 8-hydroxyquinoline, 2,2'-bipyridine, 1,10-phenanthroline, iron accumulation, reactive oxygen species
- MeSH terms
- Animals, Brain, Indans, Iron Chelating Agents, Male, Mitochondria, Monoamine Oxidase, Monoamine Oxidase Inhibitors, Pargyline, Parkinson Disease, Piperazines, Propylamines, Quinolines, Drug Delivery Systems, Rats, Sprague-Dawley, Neuroprotective Agents, Neurodegenerative Diseases, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.